Skip to content
Screener

Jazz Pharmaceuticals JAZZ Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Alkermes logo
AlkermesALKS
$486K-99.4%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$112.18M-33.9%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$50.66M-145%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$31.73M-30.6%
XER
Xeris Biopharma Holdings, Inc.XERS
-$31.09M-1,513%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$16.65B+148%
Enterprise value$21.39B+95.4%
P/S3.8×+2.1×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001232524-26-000025
Line itemThree Months Ended March 31, 20262025
Net income (loss)$293.1$(92.5)
Other comprehensive income (loss):
Foreign currency translation adjustments(82.7)162.8
Unrealized gain (loss) on cash flow hedging activities, net of income tax (benefit) expense of $— and $(0.1) respectively0.1(0.4)
Loss (gain) on cash flow hedging activities reclassified from accumulated other comprehensive loss to interest expense, net of income tax (benefit) expense of $(0.1) and $0.1 respectively0.2(0.4)
Other comprehensive income (loss)(82.4)162.0
Total comprehensive income$210.7$69.5

Item 1.Financial Statements

FAQ

What is Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Jazz Pharmaceuticals (JAZZ) reported comprehensive income (loss), net of tax, attributable to parent of $210.7M in Q1 2026.
How has Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent increased by 203.2% year-over-year, from $69.5M to $210.7M.
What is the long-term trend for Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2021 to 2025), Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a -80.4% compound annual growth rate (CAGR), from -$595.68M to $22.91M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the change in equity of a business enterprise during a period from transactions and other events from non-owner sources. It includes items such as foreign currency translation adjustments and unrealized gains or losses on hedging instruments that are not included in net income.

Ask your AI about Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude